To evaluate the effect of oxymatrine (OMT) on hepatocyte apoptosis in rats with lipopolysaccharide (LPS)/D-galactosamine (D-GalN)-induced acute liver failure (ALF). LPS/D-GalN was used to establish a model of ALF in rats. To evaluate the effect of OMT, we assessed apoptosis by transmission electron microscopy, and the pathological changes in the liver by light microscopy with hematoxylin and eosin staining. An automated biochemical analyzer was used to measure serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Enzyme-linked immunosorbent assay was used to determine the levels of tumor necrosis factor (TNF)-α and interleukin (IL)-1β. Western blotting was used to detect protein levels in liver tissues. Streptavidin peroxidase immunohistochemistry was used to observe expression of Toll-like receptor (TLR)4, active caspase-3, Bax and Bcl-2. All rats in the normal control and OMT-pretreated groups survived. The mortality rate in the model group was 30%. OMT preconditioning down-regulated apoptosis of hepatocytes and ameliorated pathological changes in liver tissue. The levels of AST, ALT, TNF-α and IL-1β in the model group increased significantly, and were significantly reduced by OMT pretreatment. OMT pretreatment down-regulated expression of TLR4 and active caspase-3 and the Bax/Bcl-2 ratio, and up-regulated expression of P-AktSer473 (Akt phosphorylated at serine 473) and P-GSK3βSer9 (glycogen synthase kinase 3β phosphorylated at serine 9) induced by LPS/D-GalN. OMT inhibits hepatocyte apoptosis by suppressing the TLR4/PI3K/Akt/GSK-3β signaling pathway, which suggests that OMT is an effective candidate for ameliorating acute liver failure.
Endometriosis is an inflammatory gynecological disorder characterized by endometrial tissue growth located outside of the uterine cavity in addition to chronic pelvic pain and infertility. In this study, we aim to develop a potential therapeutic treatment based on the pathogenesis and mechanism of Endometriosis. Our preliminary data showed that the expression of estrogen receptor β (ERβ) was significantly increased, while ERα was significantly decreased, in endometriotic cells compared to normal endometrial cells. Further investigation showed that betulinic acid (BA) treatment suppressed ERβ expression through epigenetic modification on the ERβ promoter, while had no effect on ERα expression. In addition, BA treatment suppresses ERβ target genes, including superoxide dismutase 2 (SOD2), nuclear respiratory factor-1 (NRF1), cyclooxygenase 2 (COX2), and matrix metalloproteinase-1 (MMP1), subsequently increasing oxidative stress, triggering mitochondrial dysfunction, decreasing elevated proinflammatory cytokines, and eventually suppressing endometriotic cell proliferation, mimicking the effect of ERβ knockdown. On the other hand, gain of ERβ by lentivirus infection in normal endometrial cells resulted in increased cell proliferation and proinflammatory cytokine release, while BA treatment diminished this effect through ERβ suppression with subsequent oxidative stress and apoptosis. Our results indicate that ERβ may be a major driving force for the development of endometriosis, while BA inhibits Endometriosis through specific suppression of the ERβ signaling pathway. This study provides a novel therapeutic strategy for endometriosis treatment through BA-mediated ERβ suppression.
1 January 2025 in The American Journal of Chinese Medicine
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have markedly enhanced survival rates among patients with advanced non-small cell lung cancer (NSCLC) exhibiting EGFR mutations. However, acquired resistance diminishes their therapeutic efficacy over time. Recent investigations have linked intracellular cholesterol with the emergence and advancement of various cancers. Elevated cholesterol levels could correlate with resistance to EGFR-TKIs in NSCLC. This review examines the association between cholesterol and EGFR-TKI resistance in NSCLC, with the objective of identifying more effective treatments and surmounting resistance.
Background: Ginseng (Panax ginseng C. A. Meyer) herb itself and its derived preparations (e.g. Shenmai injection) are often prescribed for cancer patients as Traditional Chinese Medicines clinically in China. Ginsenosides Rh2 and Rg3 are two of main active components of ginseng. They have significant cytotoxic effect against non-small cell lung cancer (NSCLC), but the mechanisms are not very clear, especially lack of research on the combination of cell autophagy and metabolism. This study explores the mechanism of ginsenosides Rh2 and Rg3 against NSCLC from these two aspects. Methods: In this study, we investigated the regulatory effects of ginsenosides Rh2 and Rg3 on cellular autophagy and metabolism in non-small cell lung cancer cell lines. Their regulations of cellular autophagy were detected by immunofluorescence, MDC staining, and transmission electron microscopy, while their regulations of cellular metabolism were detected by cellular metabolomics. Results: Our results showed that ginsenosides Rh2 and Rg3 can significantly induce cell autophagy, and can lead to autophagic cell death through endoplasmic reticulum stress-autophagy axis, similar to ginseng total ginsenosides extract (TGS). They also significantly regulate the cell metabolome at the same time. The regulatory effect of ginsenosides Rh2 and Rg3 on the metabolism of choline-phosphatidylcholinemay be the cellular metabolic mechanism of their cytotoxicity. Conclusion: Our findings suggested that ginsenosides Rh2 and Rg3 could induce autophagic cell death and regulate choline-phosphatidylcholine metabolism in NSCLC cells. This study has a new understanding of the antitumor mechanism of ginsenosides Rh2 and Rg3, and suggests a new direction of studying the pharmacological mechanism of natural active components.
Background and objective: Ginkgolide J is an active ingredient extracted from Ginkgo biloba leaves and has potential therapeutic effects on Alzheimer’s disease and rheumatoid arthritis. However, its pharmacokinetic behavior remains unclear. As the efficacy of an active ingredient in natural products is significantly affected by its pharmacokinetic characteristics, the pharmacokinetics of Ginkgolide J needs to be elucidated. Materials and methods: A rapid and sensitive quantitative method for Ginkgolide J using ultra-high-performance liquid chromatography-tandem mass spectrometry was established and validated. This method was then applied to pharmacokinetic studies in rats after oral and intravenous administration of a Ginkgolide J solution. Results: The linear range was 2–1000 ng/mL, with a correlation coefficient higher than 0.999. The specificity, precision, accuracy, stability, matrix effect, and recovery rate of this method met the analytical requirements. The pharmacokinetic results showed that the time to maximum plasma concentration (t max ) and half-life (t 1/2 ) after oral administration of Ginkgolide J (10 mg/kg) were 1.50 h and 3.25 h, and t 1/2 after intravenous administration (2 mg/kg) was 1.96 h, respectively. The absolute bioavailability of Ginkgolide J was 8.67%. Compared with intravenous medication, the oral bioavailability of Ginkgolide J is very low; therefore, the development of Ginkgolide J as an intravenous injection is more suitable for clinical applications. Conclusion: In this study, we established a method for analyzing Ginkgolide J based on ultra-high-performance liquid chromatography tandem mass spectrometry and measured its pharmacokinetic behavior in rats. The results showed that the oral bioavailability of Ginkgolide J is very low, and intravenous administration may be necessary for drug development.